Injection: Prevention of nausea & vomiting associated with initial & repeat courses of emetogenic cancer chemotherapy, therapy including high dose cisplatin. Prevention & treatment of postoperative nausea & vomiting. Tablet: Nausea & vomiting associated with initial & repeat courses of emetogenic cancer therapy, including high dose of cisplatin. Nausea & vomiting associated with radiation, including total body irradiation & fractionated abdominal radiation.
5-HT3 receptor antagonist; Antiemetic
Granisetron is a potent, selective antagonist of 5-HT3 receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.
Injection: Chemotherapy Induced Nausea & Vomiting: Adults: 10 mcg/kg administered intravenously within 30 minutes before initiation of chemotherapy, & only on the day(s) chemotherapy is given. Paediatric patients 2 to 16 years of age: 10 mcg/kg. Treatment of Postoperative Nausea & Vomiting: Adults: Single dose of 1 mg of Naurif should be diluted to 5 ml & administered as a slow intravenous injection (over 30 seconds). Tablet: Emetogenic chemotherapy: 2 mg once daily or 1 mg twice daily. Administered only on the days(s) chemotherapy is given. Radiation: 2 mg once daily. Two 1 mg tablets are taken within one hour of irradiation.
Granisetron does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system. As Granisetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and the half-life of granisetron.
Known hypersensitivity to granisetron.
Headache, constipation, asthenia, diarrhea, abdominal pain, dyspepsia, nausea, vomiting, dizziness, insomnia, anxiety.
Pregnancy category B. This drug may be used in pregnancy only if clearly needed.
lnjection: Store below 25°C.Protect from light.
.png&w=384&q=75)